MAPT and Alzheimer disease: However, the failure of clinical trials using β and γ-secretase inhibitors and immune therapies targeting Aβ or Tau [142], as well as the limited success of the recent trials using Aβ monoclonal antibodies to slow the progression of memory loss in patients with AD [141] have led to a reappraisal of the role of vascular dysfunction in late-life dementias [13,16,76,77].